Altimmune, Inc. ALT 深 沪
等待开盘 06-26 09:30:00 美东时间
2.865
-0.085
-2.88%
华盛通- 最 高3.045
- 今 开2.96
- 成交量 245.35万股
- 最 低 2.83
- 昨 收 2.95
- 总市值 12.38万
- 52周最高 6.4399
- 市盈率 静 --
- 换手率 5676.82%
- 52周最低 2.56
- 委 比 -8.47%
- 总股本 4.32万
- 历史最高 237.30
- 量 比 0.49
- 振 幅 7.29%
- 历史最低 1.10
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Altimmune Announces Public Offering; Quantity And Termination Date Not Disclosed
Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), as well as for working capital and general corporate
04-23 04:26
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Trump Family-Affiliated World Liberty Financial Generated $1.4 Billion In 16 Months
World Liberty Financial (CRYPTO: WLFI) has generated at least $1.4 billion for the Trump and Witkoff families since November 2024—more than Donald Trump‘s real estate empire generated in eight years.
02-09 21:40
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.
01-29 05:13
ALT5 Sigma Reports Q4 Net Earnings Of $57M
ALT5 Sigma Corporation (NASDAQ:ALTS) (the "Company"), a fintech company that maintains a strategic $WLFI digital asset treasury and provides blockchain-powered payment and trading infrastructure for digital assets,
01-12 21:25
Market-Moving News for January 5th
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
01-05 20:44
Stock Of The Day: Will The Tesla Breakout Hold?
Tesla shares have broken out. If what had been resistance converts into support it could set the stage for a move higher.
2025-12-20 02:19
Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improvement, weight loss, and strong tolerability.
2025-12-20 01:57
ALT5 Sigma Receives Expected Noncompliance Letter From Nasdaq
ALT 5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ:ALTS)(FRA: 5AR1) today announced that it received a notification letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) d
2025-12-03 05:03
12 Financials Stocks Moving In Monday's Pre-Market Session
Gainers AIFU (NASDAQ:AIFU) stock rose 12.0% to $4.35 during Monday's pre-marke...
2025-11-10 20:07
